2025 Q4 -tulosraportti

Tänään

2,25 DKK/osake

Viimeisin osinko

1,61%Tuotto/v

Tarjoustasot

Nasdaq Copenhagen

Määrä

Osto

586 492

Myynti

Määrä

577 253

Viimeisimmät kaupat

Aika	Määrä	Ostaja	Myyjä
17.59.31	219	-	-
17.59.31	259	-	-
17.59.31	293	-	-
17.59.31	219	-	-
17.59.31	192	-	-

Ylin

391

VWAP

374

Alin

366,1

VaihtoMäärä

526,2 1 406 462

VWAP

374

Ylin

391

Alin

366,1

VaihtoMäärä

526,2 1 406 462

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Ostaneet eniten

Ostaneet eniten
Välittäjä	Ostettu	Myyty	Netto	Sisäinen
Danske Bank A/S	23 066	23 066	0	23 066
Anonyymi	1 383 396	1 383 396	0	0

Myyneet eniten

Myyneet eniten
Välittäjä	Ostettu	Myyty	Netto	Sisäinen
Danske Bank A/S	23 066	23 066	0	23 066
Anonyymi	1 383 396	1 383 396	0	0

Yhtiötapahtumat

Datan lähde: FactSet, Quartr

Seuraava tapahtuma
2026 Q1 -tulosraportti 5.5.

Menneet tapahtumat
2025 Q4 -tulosraportti 25.2.
2025 Q3 -tulosraportti 6.11.2025
2025 Q2 -tulosraportti 21.8.2025
2025 Q1 -tulosraportti 8.5.2025
Vuosittainen yhtiökokous 2025 3.4.2025

Asiakkaat katsoivat myös

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.

Kirjaudu

Stock_DK
3 t sitten
·
Stock_DK
3 t sitten
·
It has gone a bit up and down, but is in the same place as 5 years ago. Shit what a boring stock
Sthaalanden8
11 t sitten
·
Sthaalanden8
11 t sitten
·
Several key figures disappoint in Q4: Revenue: €996,6m (expected €1.064,9m) EBITDA: €364,6m (expected €374,6m) EBITDA margin: 36,6 % (in line) Organic growth for 2025 ends at 7 %, but Q4 was weak – especially due to 0 % growth in Energy & Tech. Exit from Russia/Belarus pulls approx. 1 percentage point out of growth. 2026 guidance: 5–7 % organic growth (consensus 6,5 %) EBITDA margin 37–38 % Food & Health and emerging markets drive growth, and cash flow is solid (>€770m). Dividend is proposed at 4,25 kr. The stock trades around 380 kr. with high valuation (TTM P/E ~48). The case requires continued stable growth and delivered synergies to defend the multiple. It was not a bad report, but they never surprise positively and constantly show signs of weakness in the top line.
Dummepenge
5 t sitten
·
Dummepenge
5 t sitten
·
TTM p/e is not the best metric right here, as the last fiscal year was a clear EPS outlier. Furthermore, it is perhaps fairer to assess growth when it is completely cleansed of effects from exit, merger, etc. 6-7% growth with inelastic demand, a solid moat and good margins also justifies a certain premium. Otherwise, I do agree with what you so nicely write, and one must hope for somewhat more streamlined times going forward.
Newlife73
12 t sitten
·
Newlife73
12 t sitten
·
I have great respet for Mr. Friss in Millionærklubben. Always great to listen to and very inspiring. However, I strongly disagree with his long-term assessment of the potential of Danish enzyme manufacturing. The manufacturing of proteases, lipases, cellulases and more no longer requires much know-how. Any Chinese and Indian company can can do that. Whether a bacterial strain yields 20 percent more or not, it doesn't matter much in the grand scheme of things. My point is that in the medium and long term, NN will probably see the price of enzymes fall relatively significantly. Personally, I think it's a new Novo story in the longer term.
Goldielock
10 t sitten
·
Goldielock
10 t sitten
·
The former Chr. Hansen (now: Food & Health biosolutions) constitutes 45% of sales in Novonesis. Why one has not been able to create +10% growth here - and find rationalization gains to increase earnings - is incomprehensible to me, and an expression of weak management.
Mahisse
9 t sitten
·
Mahisse
9 t sitten
·
It is certainly disappointing that the so-called synergies have failed to materialize and growth has somewhat stalled in Food & Health. Management should have been able to demonstrate more value from this.
Teknikeren
14 t sitten · Muokattu
·
Teknikeren
14 t sitten · Muokattu
·
Here's what ChatGPT found regarding whether the financial report meets consensus: Here’s what’s currently known about whether Novonesis A/S’s 2025 annual report met or diverged from market consensus: 📊 Report vs. Market Expectations. 1. The official 2025 results Novonesis reported organic sales growth of ~7% and an adjusted EBITDA margin of ~37.1% for 2025. They also reiterated a solid outlook for 2026 with continued growth and margin expansion. 2. What analysts were expecting According to historical guidance by the company (which included aggregated analyst expectations), the market consensus estimates for 2025 before results were roughly: • Organic sales growth of ~6.9% • Adjusted EBITDA margin of ~37.9%. 3. Market reaction context Based on these estimates, Novonesis’ reported results were very close to consensus — the reported ~7% organic growth essentially matched expectations, while the EBITDA margin was essentially in line (slightly below some consensus figures but within the expected range). Analysts’ target prices and recommendations have shifted over time, with several reports adjusting price targets post-results, reflecting mixed sentiment about valuation and future growth even if the core results were solid. 🧠 Summary ✅ Organic sales growth: Basically in line with or slightly above market consensus. ✅ EBITDA margin: Within the expected range, very close to consensus forecasts. ⚠️ Market pricing: Analysts have adjusted price targets and views after earnings, indicating that while results broadly met expectations, sentiment about future growth or valuation may still be shifting. Bottom line: Novonesis’ 2025 annual report largely met market consensus on key financial metrics, with organic growth and earnings margin in line with pre-reported analyst estimates — though market interpretation still varies based on forward guidance and broader sentiment.
goingbador
29 min sitten
·
goingbador
29 min sitten
·
ChatGBT understands Danish perfectly...just saying...
M_LIND
15 t sitten
·
M_LIND
15 t sitten
·
Up or down today?
Baguettoblaster
14 t sitten
·
Baguettoblaster
14 t sitten
·
Yes, it will go up or down.

Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Uutiset

Viimeisin

Kaikki uutiset

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q4 -tulosraportti

Tänään

2,25 DKK/osake

Viimeisin osinko

1,61%Tuotto/v

Uutiset

Viimeisin

Kaikki uutiset

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.

Kirjaudu

Stock_DK
3 t sitten
·
Stock_DK
3 t sitten
·
It has gone a bit up and down, but is in the same place as 5 years ago. Shit what a boring stock
Sthaalanden8
11 t sitten
·
Sthaalanden8
11 t sitten
·
Several key figures disappoint in Q4: Revenue: €996,6m (expected €1.064,9m) EBITDA: €364,6m (expected €374,6m) EBITDA margin: 36,6 % (in line) Organic growth for 2025 ends at 7 %, but Q4 was weak – especially due to 0 % growth in Energy & Tech. Exit from Russia/Belarus pulls approx. 1 percentage point out of growth. 2026 guidance: 5–7 % organic growth (consensus 6,5 %) EBITDA margin 37–38 % Food & Health and emerging markets drive growth, and cash flow is solid (>€770m). Dividend is proposed at 4,25 kr. The stock trades around 380 kr. with high valuation (TTM P/E ~48). The case requires continued stable growth and delivered synergies to defend the multiple. It was not a bad report, but they never surprise positively and constantly show signs of weakness in the top line.
Dummepenge
5 t sitten
·
Dummepenge
5 t sitten
·
TTM p/e is not the best metric right here, as the last fiscal year was a clear EPS outlier. Furthermore, it is perhaps fairer to assess growth when it is completely cleansed of effects from exit, merger, etc. 6-7% growth with inelastic demand, a solid moat and good margins also justifies a certain premium. Otherwise, I do agree with what you so nicely write, and one must hope for somewhat more streamlined times going forward.
Newlife73
12 t sitten
·
Newlife73
12 t sitten
·
I have great respet for Mr. Friss in Millionærklubben. Always great to listen to and very inspiring. However, I strongly disagree with his long-term assessment of the potential of Danish enzyme manufacturing. The manufacturing of proteases, lipases, cellulases and more no longer requires much know-how. Any Chinese and Indian company can can do that. Whether a bacterial strain yields 20 percent more or not, it doesn't matter much in the grand scheme of things. My point is that in the medium and long term, NN will probably see the price of enzymes fall relatively significantly. Personally, I think it's a new Novo story in the longer term.
Goldielock
10 t sitten
·
Goldielock
10 t sitten
·
The former Chr. Hansen (now: Food & Health biosolutions) constitutes 45% of sales in Novonesis. Why one has not been able to create +10% growth here - and find rationalization gains to increase earnings - is incomprehensible to me, and an expression of weak management.
Mahisse
9 t sitten
·
Mahisse
9 t sitten
·
It is certainly disappointing that the so-called synergies have failed to materialize and growth has somewhat stalled in Food & Health. Management should have been able to demonstrate more value from this.
Teknikeren
14 t sitten · Muokattu
·
Teknikeren
14 t sitten · Muokattu
·
Here's what ChatGPT found regarding whether the financial report meets consensus: Here’s what’s currently known about whether Novonesis A/S’s 2025 annual report met or diverged from market consensus: 📊 Report vs. Market Expectations. 1. The official 2025 results Novonesis reported organic sales growth of ~7% and an adjusted EBITDA margin of ~37.1% for 2025. They also reiterated a solid outlook for 2026 with continued growth and margin expansion. 2. What analysts were expecting According to historical guidance by the company (which included aggregated analyst expectations), the market consensus estimates for 2025 before results were roughly: • Organic sales growth of ~6.9% • Adjusted EBITDA margin of ~37.9%. 3. Market reaction context Based on these estimates, Novonesis’ reported results were very close to consensus — the reported ~7% organic growth essentially matched expectations, while the EBITDA margin was essentially in line (slightly below some consensus figures but within the expected range). Analysts’ target prices and recommendations have shifted over time, with several reports adjusting price targets post-results, reflecting mixed sentiment about valuation and future growth even if the core results were solid. 🧠 Summary ✅ Organic sales growth: Basically in line with or slightly above market consensus. ✅ EBITDA margin: Within the expected range, very close to consensus forecasts. ⚠️ Market pricing: Analysts have adjusted price targets and views after earnings, indicating that while results broadly met expectations, sentiment about future growth or valuation may still be shifting. Bottom line: Novonesis’ 2025 annual report largely met market consensus on key financial metrics, with organic growth and earnings margin in line with pre-reported analyst estimates — though market interpretation still varies based on forward guidance and broader sentiment.
goingbador
29 min sitten
·
goingbador
29 min sitten
·
ChatGBT understands Danish perfectly...just saying...
M_LIND
15 t sitten
·
M_LIND
15 t sitten
·
Up or down today?
Baguettoblaster
14 t sitten
·
Baguettoblaster
14 t sitten
·
Yes, it will go up or down.

Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Nasdaq Copenhagen

Määrä

Osto

586 492

Myynti

Määrä

577 253

Viimeisimmät kaupat

Aika	Määrä	Ostaja	Myyjä
17.59.31	219	-	-
17.59.31	259	-	-
17.59.31	293	-	-
17.59.31	219	-	-
17.59.31	192	-	-

Ylin

391

VWAP

374

Alin

366,1

VaihtoMäärä

526,2 1 406 462

VWAP

374

Ylin

391

Alin

366,1

VaihtoMäärä

526,2 1 406 462

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Ostaneet eniten

Ostaneet eniten
Välittäjä	Ostettu	Myyty	Netto	Sisäinen
Danske Bank A/S	23 066	23 066	0	23 066
Anonyymi	1 383 396	1 383 396	0	0

Myyneet eniten

Myyneet eniten
Välittäjä	Ostettu	Myyty	Netto	Sisäinen
Danske Bank A/S	23 066	23 066	0	23 066
Anonyymi	1 383 396	1 383 396	0	0

Asiakkaat katsoivat myös

Yhtiötapahtumat

Datan lähde: FactSet, Quartr

Seuraava tapahtuma
2026 Q1 -tulosraportti 5.5.

Menneet tapahtumat
2025 Q4 -tulosraportti 25.2.
2025 Q3 -tulosraportti 6.11.2025
2025 Q2 -tulosraportti 21.8.2025
2025 Q1 -tulosraportti 8.5.2025
Vuosittainen yhtiökokous 2025 3.4.2025

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q4 -tulosraportti

Tänään

Uutiset

Viimeisin

Kaikki uutiset

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Yhtiötapahtumat

Datan lähde: FactSet, Quartr

Seuraava tapahtuma
2026 Q1 -tulosraportti 5.5.

Menneet tapahtumat
2025 Q4 -tulosraportti 25.2.
2025 Q3 -tulosraportti 6.11.2025
2025 Q2 -tulosraportti 21.8.2025
2025 Q1 -tulosraportti 8.5.2025
Vuosittainen yhtiökokous 2025 3.4.2025

Tuotteita joiden kohde-etuutena tämä arvopaperi

2,25 DKK/osake

Viimeisin osinko

1,61%Tuotto/v

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.

Kirjaudu

Stock_DK
3 t sitten
·
Stock_DK
3 t sitten
·
It has gone a bit up and down, but is in the same place as 5 years ago. Shit what a boring stock
Sthaalanden8
11 t sitten
·
Sthaalanden8
11 t sitten
·
Several key figures disappoint in Q4: Revenue: €996,6m (expected €1.064,9m) EBITDA: €364,6m (expected €374,6m) EBITDA margin: 36,6 % (in line) Organic growth for 2025 ends at 7 %, but Q4 was weak – especially due to 0 % growth in Energy & Tech. Exit from Russia/Belarus pulls approx. 1 percentage point out of growth. 2026 guidance: 5–7 % organic growth (consensus 6,5 %) EBITDA margin 37–38 % Food & Health and emerging markets drive growth, and cash flow is solid (>€770m). Dividend is proposed at 4,25 kr. The stock trades around 380 kr. with high valuation (TTM P/E ~48). The case requires continued stable growth and delivered synergies to defend the multiple. It was not a bad report, but they never surprise positively and constantly show signs of weakness in the top line.
Dummepenge
5 t sitten
·
Dummepenge
5 t sitten
·
TTM p/e is not the best metric right here, as the last fiscal year was a clear EPS outlier. Furthermore, it is perhaps fairer to assess growth when it is completely cleansed of effects from exit, merger, etc. 6-7% growth with inelastic demand, a solid moat and good margins also justifies a certain premium. Otherwise, I do agree with what you so nicely write, and one must hope for somewhat more streamlined times going forward.
Newlife73
12 t sitten
·
Newlife73
12 t sitten
·
I have great respet for Mr. Friss in Millionærklubben. Always great to listen to and very inspiring. However, I strongly disagree with his long-term assessment of the potential of Danish enzyme manufacturing. The manufacturing of proteases, lipases, cellulases and more no longer requires much know-how. Any Chinese and Indian company can can do that. Whether a bacterial strain yields 20 percent more or not, it doesn't matter much in the grand scheme of things. My point is that in the medium and long term, NN will probably see the price of enzymes fall relatively significantly. Personally, I think it's a new Novo story in the longer term.
Goldielock
10 t sitten
·
Goldielock
10 t sitten
·
The former Chr. Hansen (now: Food & Health biosolutions) constitutes 45% of sales in Novonesis. Why one has not been able to create +10% growth here - and find rationalization gains to increase earnings - is incomprehensible to me, and an expression of weak management.
Mahisse
9 t sitten
·
Mahisse
9 t sitten
·
It is certainly disappointing that the so-called synergies have failed to materialize and growth has somewhat stalled in Food & Health. Management should have been able to demonstrate more value from this.
Teknikeren
14 t sitten · Muokattu
·
Teknikeren
14 t sitten · Muokattu
·
Here's what ChatGPT found regarding whether the financial report meets consensus: Here’s what’s currently known about whether Novonesis A/S’s 2025 annual report met or diverged from market consensus: 📊 Report vs. Market Expectations. 1. The official 2025 results Novonesis reported organic sales growth of ~7% and an adjusted EBITDA margin of ~37.1% for 2025. They also reiterated a solid outlook for 2026 with continued growth and margin expansion. 2. What analysts were expecting According to historical guidance by the company (which included aggregated analyst expectations), the market consensus estimates for 2025 before results were roughly: • Organic sales growth of ~6.9% • Adjusted EBITDA margin of ~37.9%. 3. Market reaction context Based on these estimates, Novonesis’ reported results were very close to consensus — the reported ~7% organic growth essentially matched expectations, while the EBITDA margin was essentially in line (slightly below some consensus figures but within the expected range). Analysts’ target prices and recommendations have shifted over time, with several reports adjusting price targets post-results, reflecting mixed sentiment about valuation and future growth even if the core results were solid. 🧠 Summary ✅ Organic sales growth: Basically in line with or slightly above market consensus. ✅ EBITDA margin: Within the expected range, very close to consensus forecasts. ⚠️ Market pricing: Analysts have adjusted price targets and views after earnings, indicating that while results broadly met expectations, sentiment about future growth or valuation may still be shifting. Bottom line: Novonesis’ 2025 annual report largely met market consensus on key financial metrics, with organic growth and earnings margin in line with pre-reported analyst estimates — though market interpretation still varies based on forward guidance and broader sentiment.
goingbador
29 min sitten
·
goingbador
29 min sitten
·
ChatGBT understands Danish perfectly...just saying...
M_LIND
15 t sitten
·
M_LIND
15 t sitten
·
Up or down today?
Baguettoblaster
14 t sitten
·
Baguettoblaster
14 t sitten
·
Yes, it will go up or down.

Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Nasdaq Copenhagen

Määrä

Osto

586 492

Myynti

Määrä

577 253

Viimeisimmät kaupat

Aika	Määrä	Ostaja	Myyjä
17.59.31	219	-	-
17.59.31	259	-	-
17.59.31	293	-	-
17.59.31	219	-	-
17.59.31	192	-	-

Ylin

391

VWAP

374

Alin

366,1

VaihtoMäärä

526,2 1 406 462

VWAP

374

Ylin

391

Alin

366,1

VaihtoMäärä

526,2 1 406 462

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Ostaneet eniten

Ostaneet eniten
Välittäjä	Ostettu	Myyty	Netto	Sisäinen
Danske Bank A/S	23 066	23 066	0	23 066
Anonyymi	1 383 396	1 383 396	0	0

Myyneet eniten

Myyneet eniten
Välittäjä	Ostettu	Myyty	Netto	Sisäinen
Danske Bank A/S	23 066	23 066	0	23 066
Anonyymi	1 383 396	1 383 396	0	0

Tietoa osakekaupankäyntiin liittyvistä riskeistä

Tietoa osakekaupankäyntiin liittyvistä riskeistä

Ostaneet eniten

Myyneet eniten

Tietoa osakekaupankäyntiin liittyvistä riskeistä

Tietoa osakekaupankäyntiin liittyvistä riskeistä

Ostaneet eniten

Myyneet eniten

Tietoa osakekaupankäyntiin liittyvistä riskeistä

Tietoa osakekaupankäyntiin liittyvistä riskeistä

Ostaneet eniten

Myyneet eniten